التفاصيل البيبلوغرافية
| العنوان: |
Metadata supporting the article: Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient |
| المؤلفون: |
Maurício Fernando Silva Almeida Ribeiro (9907978), Franciele Hinterholz Knebel (9907999), Fabiana Bettoni (7436327), Rodrigo Saddi (9908002), Karina Perez Sacardo (9908005), Felipe Sales Nogueira Amorim Canedo (9907980), João Victor Machado Alessi (9908039), Andrea Kazumi Shimada (9908042), José Flávio Gomes Marin (9908044), Anamaria Aranha Camargo (8911889), Artur Katz (9908049) |
| سنة النشر: |
2021 |
| المجموعة: |
Smithsonian Institution: Digital Repository |
| مصطلحات موضوعية: |
Medicine, Cancer, Biomarkers, Biological Techniques, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Biological Sciences not elsewhere classified, epidermal growth factor receptor (EGFR), cell-free DNA, ctDNA, BRAF V600E mutation, dabrafenib, trametinib, osimertinib, combination therapy, resistance mechanism, resistance mutation, BRAF inhibitor, MEK inhibitor, metastatic lung adenocarcinoma, case report, epidermal growth factor receptor mutation |
| الوصف: |
The use of osimertinib to target epidermal growth factor receptor (EGFR) has become the standard of care in untreated EGFR-mutant non–small cell lung cancer (NSCLC) patients. Although osimertinib can be highly active, showing more durable outcomes than first-generation tyrosine kinase inhibitors (TKI), most tumors invariably become resistant, limiting its long-term clinical benefit. The present study is a case report that describes the treatment of a 50 year-old man diagnosed with a stage IV lung adenocarcinoma harbouring an EGFR activating mutation and a BRAF V600E, with dabrafenib, trametinib and osimertinib. The treatment was conducted outside a clinical trial under the patient's permission after a careful discussion regarding pros and cons of the strategy. Data access : The datasets that support the findings of this study are not publicly available in order to protect patient privacy. The data will be made available on reasonable request. For data access requests regarding the liquid biopsy (ctDNA quantification) data, please contact Dr. Franciele Knebel, email address: fhknebel@mochsl.org.br . For data access requests regarding the PET-CT high resolution images and PERCIST calculations, please contact Dr. José Marin, email address: jfgmarin@yahoo.com.br . For data access requests regarding the summary of the toxicities arising under osimertinib plus BRAF/MEK inhibition, please contact the corresponding author Dr. Maurício Ribeiro, email address: mauricio.fsaribeiro@hsl.org.br . Study approval and patient consent: This study was approved by Hospital Sírio-Libanês Ethics Committee (HSL-RC2020-16). The patient provided written informed consent for blood collection and ctDNA analysis. Study aims and methodology : Increased understanding of the relationship of concurring genomic alterations in EGFR-mutant NSCLC may enable new therapeutic opportunities upon disease progression to osimertinib. In this case report, response to dabrafenib, trametinib and osimertinib treatment was monitored, in a metastatic lung ... |
| نوع الوثيقة: |
text |
| اللغة: |
unknown |
| Relation: |
https://figshare.com/articles/online_resource/Metadata_supporting_the_article_Impressive_response_to_combination_dabrafenib_trametinib_and_osimertinib_in_a_metastatic_EGFR-mutant_BRAF_V600E_lung_adenocarcinoma_patient/13475946 |
| DOI: |
10.6084/m9.figshare.13475946.v2 |
| الاتاحة: |
https://doi.org/10.6084/m9.figshare.13475946.v2 |
| Rights: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.149AD51 |
| قاعدة البيانات: |
BASE |